Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update

Aquestive Therapeutics, Inc. (NASDAQ:AQSTGet Rating) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 2,030,000 shares, a growth of 5.7% from the February 13th total of 1,920,000 shares. Based on an average daily trading volume, of 276,400 shares, the days-to-cover ratio is currently 7.3 days.

Wall Street Analysts Forecast Growth

Separately, Wedbush upgraded Aquestive Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $3.00 to $4.00 in a report on Thursday, March 9th. Five investment analysts have rated the stock with a buy rating, Based on data from, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus target price of $8.30.

Institutional Investors Weigh In On Aquestive Therapeutics

Large investors have recently bought and sold shares of the stock. Beacon Pointe Advisors LLC acquired a new position in shares of Aquestive Therapeutics during the second quarter worth about $38,000. Mackenzie Financial Corp purchased a new position in Aquestive Therapeutics in the second quarter worth approximately $39,000. Virtu Financial LLC grew its holdings in Aquestive Therapeutics by 893.1% during the 2nd quarter. Virtu Financial LLC now owns 106,408 shares of the company’s stock worth $68,000 after acquiring an additional 95,693 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Aquestive Therapeutics by 204.7% in the 1st quarter. Renaissance Technologies LLC now owns 34,300 shares of the company’s stock valued at $90,000 after purchasing an additional 23,043 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Aquestive Therapeutics by 118.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 34,810 shares of the company’s stock valued at $91,000 after purchasing an additional 18,860 shares in the last quarter. Hedge funds and other institutional investors own 29.35% of the company’s stock.

Aquestive Therapeutics Stock Down 4.0 %

Shares of AQST opened at $0.73 on Thursday. The company has a market cap of $39.27 million, a P/E ratio of -0.64 and a beta of 2.69. Aquestive Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.95. The firm’s 50 day moving average price is $0.86 and its 200 day moving average price is $0.97.

Aquestive Therapeutics (NASDAQ:AQSTGet Rating) last posted its quarterly earnings data on Wednesday, March 8th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). The firm had revenue of $10.68 million during the quarter, compared to analyst estimates of $9.93 million. During the same quarter in the prior year, the company earned ($0.38) earnings per share. Research analysts forecast that Aquestive Therapeutics will post -0.78 earnings per share for the current year.

About Aquestive Therapeutics

(Get Rating)

Aquestive Therapeutics, Inc engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Featured Stories

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with's FREE daily email newsletter.